Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab
-
Published:2022-09-09
Issue:1
Volume:17
Page:86-96
-
ISSN:1936-0533
-
Container-title:Hepatology International
-
language:en
-
Short-container-title:Hepatol Int
Author:
Hatanaka TakeshiORCID, Kakizaki SatoruORCID, Hiraoka AtsushiORCID, Tada ToshifumiORCID, Hirooka Masashi, Kariyama Kazuya, Tani Joji, Atsukawa Masanori, Takaguchi Koichi, Itobayashi Ei, Fukunishi Shinya, Tsuji Kunihiko, Ishikawa ToruORCID, Tajiri KazutoORCID, Ochi Hironori, Yasuda Satoshi, Toyoda HidenoriORCID, Ogawa Chikara, Nishimura TakashiORCID, Shimada Noritomo, Kawata KazuhitoORCID, Kosaka HisashiORCID, Tanaka Takaaki, Ohama Hideko, Nouso Kazuhiro, Morishita AsahiroORCID, Tsutsui Akemi, Nagano Takuya, Itokawa Norio, Okubo Tomomi, Arai Taeang, Imai Michitaka, Naganuma AtsushiORCID, Koizumi Yohei, Nakamura Shinichiro, Kaibori MasakiORCID, Iijima HirokoORCID, Hiasa YoichiORCID, Kumada TakashiORCID,
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–1905 2. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–1173 3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390 4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34 5. Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology 2021;73(Suppl 1):158–191
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|